

# Tanios Bekaii-Saab

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10009411/publications.pdf>

Version: 2024-02-01

219  
papers

12,590  
citations

36303

51  
h-index

29157

104  
g-index

225  
all docs

225  
docs citations

225  
times ranked

20737  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet</i> , The, 2020, 395, 1907-1918.	13.7	1,395
2	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2016, 387, 545-557.	13.7	878
3	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282.	1.6	524
4	IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. <i>Gut</i> , 2018, 67, 320-332.	12.1	381
5	Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer. <i>JAMA Surgery</i> , 2016, 151, e161137.	4.3	365
6	Pancreatic Cancer-Associated Stellate Cells Promote Differentiation of Myeloid-Derived Suppressor Cells in a STAT3-Dependent Manner. <i>Cancer Research</i> , 2013, 73, 3007-3018.	0.9	340
7	Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 446-453.	10.7	322
8	Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 1015-1027.	1.6	301
9	Biliary cancer: Utility of nextâ€¢generation sequencing for clinical management. <i>Cancer</i> , 2016, 122, 3838-3847.	4.1	289
10	Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers. <i>Journal of Clinical Oncology</i> , 2011, 29, 2357-2363.	1.6	272
11	Pain, depression, and fatigue: Loneliness as a longitudinal risk factor.. <i>Health Psychology</i> , 2014, 33, 948-957.	1.6	234
12	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 782-794.	6.3	223
13	Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas. <i>Annals of Surgical Oncology</i> , 2015, 22, 1153-1159.	1.5	215
14	Colon Cancer, Version 3.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1028-1059.	4.9	192
15	Rectal Cancer, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 719-728.	4.9	181
16	A multiâ€¢institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. <i>Cancer</i> , 2013, 119, 2692-2700.	4.1	168
17	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021, 7, 1167.	7.1	149
18	Gastric Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 378-409.	4.9	140

#	ARTICLE	IF	CITATIONS
19	Rectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1528-1564.	4.9	138
20	Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy. Cancer Immunology, Immunotherapy, 2011, 60, 1269-1279.	4.2	134
21	Appendiceal Mucinous Neoplasms: Diagnosis and Management. Oncologist, 2017, 22, 1107-1116.	3.7	131
22	Metastatic Colon Cancer, Version 3.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 141-152.	4.9	130
23	Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma. JAMA Oncology, 2020, 6, e204930.	7.1	124
24	Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. Cancer Research, 2017, 77, 2647-2660.	0.9	113
25	STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH+/CD133+ stem cell-like human colon cancer cells. Biochemical and Biophysical Research Communications, 2011, 416, 246-251.	2.1	112
26	UDP-Glucuronosyltransferase (UGT) 2B15 Pharmacogenetics: UGT2B15 D85Y Genotype and Gender Are Major Determinants of Oxazepam Glucuronidation by Human Liver. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 656-665.	2.5	105
27	A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clinical Cancer Research, 2016, 22, 61-68.	7.0	105
28	Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. Cancer Immunology, Immunotherapy, 2015, 64, 149-159.	4.2	104
29	Carbohydrate antigen 19â€9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabineâ€containing chemotherapy. Cancer, 2013, 119, 285-292.	4.1	103
30	A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas. Clinical Cancer Research, 2009, 15, 5895-5901.	7.0	101
31	HER2/neu May Not Be an Interesting Target in Biliary Cancers: Results of an Early Phase II Study with Lapatinib. Oncology, 2012, 82, 175-179.	1.9	96
32	Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. Nature Communications, 2017, 8, 14755.	12.8	96
33	Identifying and targeting cancer stem cells in the treatment of gastric cancer. Cancer, 2017, 123, 1303-1312.	4.1	89
34	Prostate cancer incidence in males with Lynch syndrome. Genetics in Medicine, 2014, 16, 553-557.	2.4	88
35	Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. Scientific Reports, 2015, 5, 10867.	3.3	87
36	Cholangiocarcinoma With <i>FGFR</i> Genetic Aberrations: A Unique Clinical Phenotype. JCO Precision Oncology, 2018, 2, 1-12.	3.0	86

#	ARTICLE	IF	CITATIONS
37	Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. <i>Oncologist</i> , 2015, 20, 1132-1139.	3.7	84
38	Localized Colon Cancer, Version 3.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 519-528.	4.9	81
39	Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv274.	6.3	80
40	Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2565-2574.	7.0	80
41	Fractionated radioimmunotherapy with <sup>90</sup> Y- $\epsilon$ livatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer. <i>Cancer</i> , 2012, 118, 5497-5506.	4.1	79
42	Ampullary Cancer: An Overview. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 112-115.	3.8	78
43	Antiangiogenic Therapy in Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2018, 24, 165-170.	2.0	77
44	Anal Carcinoma, Version 2.2012. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 449-454.	4.9	67
45	The Role of Maintenance Strategies in Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, e194489.	7.1	65
46	Clinical Trials and Progress in Metastatic Colon Cancer. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 349-365.	1.5	64
47	A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2018, 23, 25-34.	3.7	63
48	A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603). <i>Oncologist</i> , 2010, 15, 1310-1319.	3.7	58
49	Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. <i>Scientific Reports</i> , 2015, 5, 12122.	3.3	58
50	Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells. <i>Anti-Cancer Drugs</i> , 2009, 20, 444-449.	1.4	57
51	Predictors of Pancreatic Cancer-Associated Weight Loss and Nutritional Interventions. <i>Pancreas</i> , 2017, 46, 1152-1157.	1.1	57
52	Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. <i>Clinical Colorectal Cancer</i> , 2019, 18, e117-e129.	2.3	53
53	Colon Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1238-1290.	4.9	52
54	Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1499-1506.	2.3	51

#	ARTICLE	IF	CITATIONS
55	Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report. <i>Journal of Hematology and Oncology</i> , 2008, 1, 18.	17.0	50
56	Incidence of Minimally Invasive Colorectal Cancer Surgery at National Comprehensive Cancer Network Centers. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju362-dju362.	6.3	48
57	Optimal Management of Gastric Cancer. <i>Annals of Surgery</i> , 2014, 259, 102-108.	4.2	48
58	Mixed Adeno-neuroendocrine Carcinoma: An Aggressive Clinical Entity. <i>Annals of Surgical Oncology</i> , 2016, 23, 2281-2286.	1.5	48
59	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2022, 5, e2149040.	5.9	48
60	Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 727-736.	4.2	47
61	Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 293-301.	1.4	47
62	A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. <i>BMC Cancer</i> , 2006, 6, 278.	2.6	46
63	IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. <i>Clinical Cancer Research</i> , 2017, 23, 489-502.	7.0	46
64	A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 75-82.	3.2	46
65	Incidence and Survival of Appendiceal Mucinous Neoplasms. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 569-573.	1.3	45
66	Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. <i>Cancer Treatment Reviews</i> , 2017, 60, 109-119.	7.7	45
67	Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 3495-3507.	7.0	43
68	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. <i>JAMA Network Open</i> , 2022, 5, e224304.	5.9	43
69	Defining Surgical Quality in Gastric Cancer: A RAND/UCLA Appropriateness Study. <i>Journal of the American College of Surgeons</i> , 2013, 217, 347-357e1.	0.5	42
70	Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. <i>Investigational New Drugs</i> , 2014, 32, 113-122.	2.6	42
71	Nextâ€­generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. <i>Cancer</i> , 2016, 122, 3657-3666.	4.1	41
72	Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2403-2413.	7.0	40

#	ARTICLE	IF	CITATIONS
73	Peptide Vaccines and Peptidomimetics of EGFR (HER-1) Ligand Binding Domain Inhibit Cancer Cell Growth In Vitro and In Vivo. <i>Journal of Immunology</i> , 2013, 191, 217-227.	0.8	39
74	Systemic Therapy for Advanced Appendiceal Adenocarcinoma: An Analysis From the NCCN Oncology Outcomes Database for Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1123-1130.	4.9	37
75	Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway. <i>Oncogene</i> , 2018, 37, 3440-3455.	5.9	37
76	CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. <i>Future Oncology</i> , 2019, 15, 1295-1302.	2.4	37
77	Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	3.0	37
78	Incorporation of photodynamic therapy as an induction modality in non-small cell lung cancer. <i>Lasers in Surgery and Medicine</i> , 2006, 38, 881-889.	2.1	36
79	Processes of Care in the Multidisciplinary Treatment of Gastric Cancer. <i>JAMA Surgery</i> , 2014, 149, 18.	4.3	36
80	Appendiceal Mixed Adeno-Neuroendocrine Carcinoma: A Population-Based Study of the Surveillance, Epidemiology, and End Results Registry. <i>Frontiers in Oncology</i> , 2016, 6, 148.	2.8	33
81	Autophagy Induction Results in Enhanced Anoikis Resistance in Models of Peritoneal Disease. <i>Molecular Cancer Research</i> , 2017, 15, 26-34.	3.4	32
82	Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 309-316.	4.1	32
83	Multi-Omics Data Analysis of Gene Expressions and Alterations, Cancer-Associated Fibroblast and Immune Infiltrations, Reveals the Onco-Immune Prognostic Relevance of STAT3/CDK2/4/6 in Human Malignancies. <i>Cancers</i> , 2021, 13, 954.	3.7	32
84	ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3641-3648.	7.0	32
85	Selumetinib for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 111-123.	4.1	31
86	Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 344-356.	4.1	31
87	Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses. <i>Genetics in Medicine</i> , 2016, 18, 863-868.	2.4	30
88	Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome. <i>Cancer Research and Treatment</i> , 2016, 48, 596-604.	3.0	30
89	Secondâ€line treatment in patients with pancreatic ductal adenocarcinoma: A metaâ€analysis. <i>Cancer</i> , 2017, 123, 4680-4686.	4.1	29
90	Seeing the forest through the trees: A systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 9-34.	4.4	27

#	ARTICLE	IF	CITATIONS
91	Therapeutic Targeting Strategies of Cancer Stem Cells in Gastrointestinal Malignancies. <i>Biomedicines</i> , 2019, 7, 17.	3.2	27
92	Gastric Cancer Clinical Practice Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 350.	4.9	27
93	Yttrium-90 Radioembolization as Salvage Therapy for Colorectal Cancer With Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2012, 11, 195-199.	2.3	26
94	A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 685-695.	2.6	26
95	Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. <i>Pancreas</i> , 2020, 49, 193-200.	1.1	26
96	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 1109-1117.	3.7	25
97	Esophageal Cancer Clinical Practice Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 328.	4.9	25
98	A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2012, 30, 629-638.	2.6	24
99	Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. <i>Pancreatology</i> , 2019, 19, 80-87.	1.1	24
100	Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer. <i>Medical Oncology</i> , 2012, 29, 3101-3107.	2.5	23
101	Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. <i>Cancer</i> , 2014, 120, 1780-1786.	4.1	23
102	Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2020, 132, 112-121.	2.8	22
103	Perineural Invasion Predicts for Distant Metastasis in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation and Surgery. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 561-568.	1.3	21
104	Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor. <i>EMBO Molecular Medicine</i> , 2020, 12, e9910.	6.9	21
105	A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. <i>Investigational New Drugs</i> , 2022, 40, 134-141.	2.6	21
106	Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. <i>Scientific Reports</i> , 2020, 10, 22087.	3.3	21
107	<i>BRAF</i> -Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape. <i>Journal of Clinical Oncology</i> , 2022, 40, 2706-2715.	1.6	21
108	Influence of <i>KRAS</i> mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma. <i>Cancer</i> , 2012, 118, 6243-6252.	4.1	20



#	ARTICLE	IF	CITATIONS
109	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. Medical Oncology, 2016, 33, 48.	2.5	20
110	Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. Journal of the National Cancer Institute, 2016, 108, djv437.	6.3	20
111	Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. Oncoimmunology, 2020, 9, 1818437.	4.6	20
112	Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. Oncologist, 2021, 26, 668-675.	3.7	20
113	Integrating anti-EGFR therapies in metastatic colorectal cancer. Journal of Gastrointestinal Oncology, 2013, 4, 285-98.	1.4	20
114	Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2010, 66, 1019-1029.	2.3	19
115	Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer. Investigational New Drugs, 2011, 29, 347-351.	2.6	19
116	Clinical update on K-Ras targeted therapy in gastrointestinal cancers. Critical Reviews in Oncology/Hematology, 2018, 130, 78-91.	4.4	19
117	Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer. Cancers, 2019, 11, 1068.	3.7	19
118	A clinical trial protocol paper discussing the BRIGHTER study. Future Oncology, 2018, 14, 901-906.	2.4	18
119	First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. European Journal of Cancer, 2021, 151, 14-24.	2.8	18
120	A Dose Escalation and Pharmacodynamic Study of Triapine and Radiation in Patients With Locally Advanced Pancreas Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, e475-e481.	0.8	17
121	Optimizing Neoadjuvant Therapy for Rectal Cancer With Oxaliplatin. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 298-307.	4.9	17
122	Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1528-1534.	4.9	17
123	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Pancreatology, 2020, 20, 101-109.	1.1	17
124	Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors. Chinese Clinical Oncology, 2020, 9, 6-6.	1.2	17
125	Improvements in Clinical Outcomes for BRAFV600E-Mutant Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 4435-4441.	7.0	17
126	Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42. Neoplasia, 2016, 18, 765-774.	5.3	16



#	ARTICLE	IF	CITATIONS
127	Adjuvant therapy for pancreas cancer in an era of value based cancer care. <i>Cancer Treatment Reviews</i> , 2016, 42, 10-17.	7.7	16
128	Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. <i>BMC Cancer</i> , 2017, 17, 262.	2.6	16
129	Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. <i>Cancers</i> , 2018, 10, 193.	3.7	16
130	Development and Validation of a Nomogram for Early Detection of Malignant Gallbladder Lesions. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00098.	2.5	16
131	Practical considerations in the use of regorafenib in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095686.	3.2	16
132	A Rare <i>EGFR</i> – <i>SEPT14</i> Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib. <i>Oncologist</i> , 2020, 25, 203-207.	3.7	16
133	A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN G14-186. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3337-3348.	4.2	16
134	Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). <i>Vaccines</i> , 2015, 3, 519-543.	4.4	15
135	Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at National Comprehensive Cancer Network centers. <i>Advances in Radiation Oncology</i> , 2018, 3, 34-41.	1.2	15
136	Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. <i>Oncotarget</i> , 2015, 6, 44509-44522.	1.8	15
137	Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2010, 5, 713-718.	1.1	14
138	What provider volumes and characteristics are appropriate for gastric cancer resection? Results of the International RAND/UCLA expert panel. <i>Surgery</i> , 2013, 154, 1100-1109.	1.9	14
139	Neoadjuvant Radiotherapy Use in Locally Advanced Rectal Cancer at NCCN Member Institutions. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 235-243.	4.9	14
140	Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 614-618.	1.3	14
141	Application of next-generation sequencing in gastrointestinal and liver tumors. <i>Cancer Letters</i> , 2016, 374, 187-191.	7.2	14
142	Gemcitabine-Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine. <i>Clinical Colorectal Cancer</i> , 2017, 16, e119-e122.	2.3	14
143	A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1174-1179.	3.7	14
144	Genomic diversity of colorectal cancer: Changing landscape and emerging targets. <i>World Journal of Gastroenterology</i> , 2016, 22, 5668.	3.3	14

#	ARTICLE	IF	CITATIONS
145	Hepatobiliary Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 728.	4.9	14
146	Outcomes in Patients with Obstructive Jaundice from Metastatic Colorectal Cancer and Implications for Management. Journal of Gastrointestinal Surgery, 2014, 18, 2186-2191.	1.7	13
147	Therapeutic options for intrahepatic cholangiocarcinoma. Hepatobiliary Surgery and Nutrition, 2017, 6, 91-100.	1.5	13
148	Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Clinical Cancer Research, 2020, 26, 3117-3125.	7.0	13
149	Frontline therapy for advanced hepatocellular carcinoma: an update. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210861.	3.2	13
150	A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2010, 66, 151-158.	2.3	12
151	A RAND/UCLA Appropriateness Study of the Management of Familial Gastric Cancer. Annals of Surgical Oncology, 2013, 20, 533-541.	1.5	12
152	Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. Pancreatology, 2020, 20, 1115-1122.	1.1	12
153	Late Relapse of Ovarian Dysgerminoma: Case Report and Literature Review. Gynecologic Oncology, 1999, 72, 111-112.	1.4	11
154	The Efficacy of Adjuvant Chemotherapy in Patients With Stage II/III Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 531-534.	1.3	11
155	Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer. Small GTPases, 2018, 9, 452-456.	1.6	11
156	The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies. Biomedicines, 2017, 5, 10.	3.2	10
157	Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?. Seminars in Liver Disease, 2021, 41, 136-141.	3.6	10
158	Isocitrate Dehydrogenase-“Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes. JCO Precision Oncology, 2022, 6, e2100156.	3.0	10
159	Emerging Treatments in Recurrent and Metastatic Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, S-18-S-27.	4.9	9
160	A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin. Journal of Gastrointestinal Oncology, 2018, 9, 1063-1073.	1.4	9
161	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. JAMA Network Open, 2022, 5, e2142046.	5.9	9
162	An Update on Biochemotherapy of Advanced Gastric and Gastroesophageal Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 895-900.	4.9	8

#	ARTICLE	IF	CITATIONS
163	A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTx) in previously untreated patients with metastatic adenocarcinoma of the pancreas. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 511-517.	2.3	8
164	Should Combination Chemotherapy Serve as the Backbone in Clinical Trials of Advanced Pancreatic Cancer?. <i>Pancreas</i> , 2014, 43, 343-349.	1.1	8
165	Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2016, Volume 6, 21-30.	5.5	8
166	Outcomes of definitive chemoradiation in patients with esophageal cancer. <i>Ecological Management and Restoration</i> , 2016, 30, 1-7.	0.4	8
167	Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1. <i>Pancreatology</i> , 2021, 21, 192-199.	1.1	8
168	Successful Completion of Adjuvant Chemotherapy in a Patient With Colon Cancer Experiencing 5-Fluorouracil-Induced Cardiac Vasospasm. <i>Clinical Colorectal Cancer</i> , 2016, 15, e61-e63.	2.3	7
169	Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. <i>International Journal of Cancer</i> , 2018, 142, 1671-1675.	5.1	7
170	Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet?. <i>Oncotarget</i> , 2015, 6, 22206-22213.	1.8	7
171	Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors. <i>Oncotarget</i> , 2016, 7, 5306-5312.	1.8	7
172	Therapeutic Advances in Pancreatic Cancer: Miles to Go Before We Sleep. <i>Journal of the National Cancer Institute</i> , 2015, 107, dju439-dju439.	6.3	6
173	The Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer. <i>JAMA Oncology</i> , 2022, 8, 1257.	7.1	6
174	Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 319-324.	2.3	5
175	O-0002 A Phase 2 Adjuvant Trial of GI-4000 Plus Gemcitabine vs. Gemcitabine Alone in Ras+ Patients with Resected Pancreas Cancer: R1 Subgroup Analysis. <i>Annals of Oncology</i> , 2012, 23, iv5.	1.2	5
176	A Phase I Dose Escalation and Pharmacodynamic Study of SU5416 (Semaxanib) Combined with Weekly Cisplatin and Irinotecan in Patients with Advanced Solid Tumors. <i>Onkologie</i> , 2013, 36, 6-6.	0.8	5
177	The Addition of Radiation to Chemotherapy does not Improve Outcome When Compared to Chemotherapy in the Treatment of Resected Pancreas Cancer: The Results of a Single-Institution Experience. <i>Annals of Surgical Oncology</i> , 2014, 21, 862-867.	1.5	5
178	Moving Forward With Expanding to an "All-RAS" Mutational Analysis in Metastatic Colorectal Cancer: Beyond KRAS Mutations. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 299-300.	4.9	5
179	Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 140-146.	1.3	5
180	Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. <i>Oncologist</i> , 2021, 26, 610-618.	3.7	5

#	ARTICLE	IF	CITATIONS
181	Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer and Exposureâ€”Safety Analyses in Patients With Metastatic Pancreatic Cancer. CPT: Pharmacometrics and Systems Pharmacology, 2021, , .	2.5	5
182	Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer. Expert Opinion on Investigational Drugs, 2022, 31, 437-441.	4.1	5
183	KRAS Testing in Metastatic Colorectal Cancer: Implications on the Use of Biologic Agents. Clinical Colorectal Cancer, 2009, 8, 135-140.	2.3	4
184	A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer, 2013, 79, 27-32.	2.0	4
185	FOLFIRINOX in Locally Advanced Pancreas Adenocarcinoma: Back to the Future?. Oncologist, 2013, 18, 487-489.	3.7	4
186	MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches. OncoTargets and Therapy, 2016, Volume 9, 5931-5941.	2.0	4
187	Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors. Targeted Oncology, 2016, 11, 807-814.	3.6	4
188	Signaling pathways as therapeutic targets in biliary tract cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 485-498.	3.4	4
189	Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease. British Journal of Cancer, 2020, 123, 1377-1386.	6.4	4
190	Optimizing Chemotherapy Choice in the Treatment of Advanced Pancreatic Cancerâ€”It Is Complicated. JAMA Network Open, 2021, 4, e2134458.	5.9	4
191	FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. Digestive Diseases and Sciences, 2022, 67, 3797-3805.	2.3	4
192	Photodynamic Therapy (PDT) May Provide Effective Palliation in the Treatment of Primary Tracheal Carcinoma: A Small Case Series. Photomedicine and Laser Surgery, 2012, 30, 668-671.	2.0	3
193	Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. Cancer Chemotherapy and Pharmacology, 2015, 76, 1005-1012.	2.3	3
194	Maintenance Therapy for Colorectal Cancer: Which Regimen and Which Patients?. Drugs, 2015, 75, 1833-1842.	10.9	3
195	Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. Oncologist, 2020, 25, e1246-e1248.	3.7	3
196	Recurrent Life-Threatening Deep Tissue Hematomas After Switching to Generic Enoxaparin: A Report and Perspective on the Approval Process for Biological Compounds. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 104-106.	1.7	2
197	Second-line outcomes in metastatic colorectal cancer â€” raising the bar for the high jump rather than the doing the limbo. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 133-143.	1.4	2
198	Watch and Wait in Rectal Cancer: Whoâ€™s In and Whoâ€™s Out?. Journal of Oncology Practice, 2019, 15, 133-134.	2.5	2

#	ARTICLE	IF	CITATIONS
199	CA 19-9 as a Serum Biomarker in Cancer. Biomarkers in Disease, 2015, , 179-201.	0.1	2
200	A phase II study of biweekly pralatrexate and docetaxel in patients with advanced esophageal and gastroesophageal carcinoma that have failed first-line platinum-based therapy. Journal of Gastrointestinal Oncology, 2015, 6, 336-40.	1.4	2
201	Antiemetic Control with Palonosetron in Patients with Gastrointestinal Cancer Receiving a Fluoropyrimidine-Based Regimen in Addition to Either Irinotecan or Oxaliplatin: A Retrospective Study. Oncology, 2012, 83, 135-140.	1.9	1
202	Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience. Medical Oncology, 2016, 33, 4.	2.5	1
203	Competitive Funding Strategies for the Conquer Cancer Foundation of ASCO. Journal of Oncology Practice, 2017, 13, e62-e67.	2.5	1
204	The Role of Maintenance Therapy in Metastatic Colorectal Cancerâ€”Reply. JAMA Oncology, 2020, 6, 937.	7.1	1
205	AJCC 8th edition staging system for pathologically versus clinically staged intrahepatic cholangiocarcinoma (iCCA): ready for prime time?. Chinese Clinical Oncology, 2019, 8, S19-S19.	1.2	1
206	A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies. Cancer Chemotherapy and Pharmacology, 2010, 65, 863-869.	2.3	0
207	A phase I study of topotecan and gemcitabine in advanced solid tumors. Investigational New Drugs, 2011, 29, 1390-1394.	2.6	0
208	Adjuvant Therapy Following Curative Resection of Metastases. Current Colorectal Cancer Reports, 2012, 8, 217-224.	0.5	0
209	<i>RAS</i> mutations: impact on treatment outcome. Colorectal Cancer, 2013, 2, 525-534.	0.8	0
210	CA 19-9 as a Serum Biomarker in Cancer. , 2014, , 1-19.		0
211	Taking aim at the genomic diversity of gastrointestinal cancers: a changing landscape. Journal of Gastrointestinal Oncology, 2016, 7, 673-674.	1.4	0
212	Adjuvant Chemotherapy for Rectal Cancer After Neoadjuvant Treatment: FOLFOX, 5-FU, or Observation. Current Colorectal Cancer Reports, 2016, 12, 260-265.	0.5	0
213	Response to Drs Von Hoff and Renschler. Therapeutic Advances in Medical Oncology, 2017, 9, 445-446.	3.2	0
214	Comparison of Therapy in Advanced Hepatocellular Carcinoma Based on Clear Definition and Accurate Subgroup Dataâ€”Reply. JAMA Oncology, 2021, 7, 941.	7.1	0
215	Systemic Treatment for Metastatic or Recurrent Disease. , 2020, , 275-287.		0
216	Precision Medicine in Metastatic Colorectal Cancerâ€”Finding and Hitting the Right Targets. Oncology & Hematology Review, 2020, 16, 36.	0.2	0

#	ARTICLE	IF	CITATIONS
217	ZEBRA: An IRCI/ACCRU (RU021502I) Multicenter Phase II Study of Pembrolizumab in Patients With Advanced Small Bowel Adenocarcinoma (SBA). SSRN Electronic Journal, 0, , .	0.4	0
218	Editorial comment on: Systemic treatment of hepatocellular carcinoma: An EASL position paper. Hepatobiliary Surgery and Nutrition, 2021, 11, 0-0.	1.5	0
219	OUP accepted manuscript. Oncologist, 2022, , .	3.7	0